Inventor · disambiguated record
Srinivasan Thangathirupathy
Also filed as: THANGATHIRUPATHY SRINIVASAN
13 granted patents·10 pending applications·35 citations·filing 2012–2021
88Inventor score
Top patents by PatentIndex Score
23 records- 0194US9790169B2IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Oct 17, 2017·19 cites·27 claims
- 0289US9221796B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2015·Granted Dec 29, 2015·5 cites·12 claims
- 0388US10959986B2Inhibitors of indoleamine 2,3-dioxygenase and methods of their useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 30, 2021·3 cites·42 claims
- 0482US10399932B2Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancerBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Sep 3, 2019·3 cites·13 claims
- 0580US11253525B2Inhibitors of indoleamine 2,3-dioxygenase and methods of their useBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Feb 22, 2022·1 cites·32 claims
- 0675US10167254B2IDO inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2017·Granted Jan 1, 2019·1 cites·43 claims
- 0773US8722670B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2012·Granted May 13, 2014·2 cites·13 claims
- 0873US2021121453A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 0971US10344020B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Jul 9, 2019·1 cites·13 claims
- 1069US2020163949A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2020·Application pending·0 cites
- 1169US2019314358A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Application pending·0 cites
- 1268US10954225B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 23, 2021·0 cites·4 claims
- 1368US2019117638A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1466US2018250283A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2018·Application pending·0 cites
- 1565US2018000807A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 1665US2018110766A1Selective nr2b antagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 1764US10961229B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2019·Granted Mar 30, 2021·0 cites·12 claims
- 1864US2017258777A1Selective NR2B AntagonistsBRISTOL MYERS SQUIBB CO·Filed 2017·Application pending·0 cites
- 1959US2016081995A1Selective NR2B AntagonistsBRISTOL MYERS SQUIBB CO·Filed 2015·Application pending·0 cites
- 2056US10501451B2Selective NR2B antagonistsBRISTOL MYERS SQUIBB CO·Filed 2016·Granted Dec 10, 2019·0 cites·19 claims
- 2146US12473304B2Heterocyclic PAD4 inhibitorsBRISTOL MYERS SQUIBB CO·Filed 2021·Granted Nov 18, 2025·0 cites·29 claims
- 2237US10221129B2Inhibitors of human immunodeficiency virus replicationVIIV HEALTHCARE UK NO 5 LTD·Filed 2016·Granted Mar 5, 2019·0 cites·20 claims
- 2335US2018072997A1Inhibitors of human immunodeficiency virus replicationVIIV HEATHCARE UK NO 5 LTD·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Srinivasan Thangathirupathy files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →